Clinical Trial

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Recruiting
View on ClinicalTrials.gov →
Summary
To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.
Protocol Amendment History 4 changes
notable Enrollment increased: 120 -> 458 participants 2026-08-08
minor Trial arms changed: 7 -> 8 2026-08-08
notable Primary completion pushed: 2026-01-30 -> 2028-01-30 2026-08-08
minor Completion pushed: 2026-06-30 -> 2028-06-30 2026-08-08
Trial Details
NCT Number NCT06265545
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions AML, Refractory, Relapsed
Enrollment 458 participants
Start Date 2024-02-22
Primary Completion 2028-01-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-07